TCW Letter Highlights BioMarin’s Valuation Measures
The mid-cap fund listed BioMarin as a 2.55% holding and said it met three valuation characteristics when the fund initiated its position.
BioMarin Pharmaceutical was among the companies highlighted in TCW Relative Value Mid Cap Fund’s second-quarter 2026 investor letter. The letter listed the biotechnology company as a 2.55% holding.
TCW said BioMarin met three of five valuation characteristics when the fund initiated its position during the quarter. Those measures were price-to-earnings, price-to-cash-flow and price-to-book.
The fund described BioMarin as focused on developing and commercializing medicines for people with rare, genetically defined diseases. Its portfolio includes enzyme replacement therapies and small-molecule drugs, according to the letter.
BioMarin shares closed at $60 on September 30, giving the company a market capitalization of $11.61 billion, according to the article. The stock’s reported 52-week range was $49.26 to $170.98.
This article was produced with the help of AI technology.
Source: Yahoo Finance
